Original Article

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations

Hope Northrup, MD a, Mary E. Aronow, MD b, E. Martina Bebin, MD, MPA c, John Bissler, MD d, Thomas N. Darling, MD, PhD e, Petrus J. de Vries, MBChB, MRCPsych, PhD f, Michael D. Frost, MD g, Zoë Fuchs h, Elizabeth S. Gosnell, DMD, MS i, Nishant Gupta, MD j, Anna C. Jansen, MD, PhD k, Sergiusz Jóźwiak, MD, PhD l, J. Chris Kingswood, MSc m, Timothy K. Knilans, MD n, Francis X. McCormack, MD o, Ashley Pouunders, MSN, FNP-C o, Steven L. Roberds, PhD h, David F. Rodriguez-Buritica, MD p, Jonathan Roth, MD q, Julian R. Sampson, DM r, Steven Sparagana, MD s, Elizabeth Anne Thiele, MD, PhD t, Howard L. Weiner, MD u, James W. Wheless, MD v, Alexander J. Towbin, MD w, Darcy A. Krueger, MD, PhD x, *, on behalf of the International Tuberous Sclerosis Complex Consensus Group#

a Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas
b Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts
c Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama
d Department of Pediatrics, University of Tennessee Health Science Center and Le Bonheur Children’s Hospital, Memphis, Tennessee
e Uniformed Services University of the Health Sciences, Bethesda, Maryland
f Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa

© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of original article: https://doi.org/10.1016/j.pediatrneurol.2021.07.010.

* Communications should be addressed to: Dr. Krueger; Department of Neurology; Division of Pediatrics; Cincinnati Children’s Hospital Medical Center; 3333 Burnet Avenue; Cincinnati, OH 45229.

E-mail address: darcy.krueger@cchmc.org (D.A. Krueger).


https://doi.org/10.1016/j.pediatrneurol.2021.07.013

0887-8994/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Tuberous sclerosis complex (TSC) is a rare genetic disorder that can affect any organ system. Many manifestations can be associated with severe morbidity and potentially death, so early diagnosis and appropriate lifelong surveillance and management are crucial. Given that the clinical manifestations of TSC are varied in age of onset and the extent of systemic involvement and severity, TSC clinical features may present dynamically over the course of an individual's life. The incidence of TSC has been estimated many times and generally falls between 1:6000 and 1:10,000 live births. A comprehensive study in the United Kingdom estimated the incidence at 1:5800 live births, and a more recent study in Germany using the most recent diagnostic criteria estimated the incidence rate from 1:6760 to 1:13,520 live births. Major updates to clinical consensus guidelines for the diagnosis, surveillance, and management of TSC were published in 1998, 1999, and 2013. Recognizing that many new clinical studies and important new drug approvals had occurred or were pending, chairs and cochairs of working groups involved in the 2012 TSC Clinical Consensus Conference met over two days at the 2018 World TSC Conference organized by the TSC Alliance in collaboration with TSC International (TSCi). Each disease area of TSC was reviewed by the chairs and cochairs of working groups involved in the 2012 TSC Consensus Group were asked to review and affirm recommendations to be continued from 2012, providing additional clarity or emphasis when necessary to address unintended ambiguity or unanticipated obstacles to implementation that had since emerged. Working group deliberations and drafting of updated recommendations continued between 2018 and 2021, culminating in the current document. The result of these efforts is reported here as current consensus guidelines for the diagnosis, surveillance, and management of TSC.

Methods

Updating these guidelines employed the structure and methods as described for the previous update with two exceptions. First, additional experts were consulted either to replace participants in the previous update who were no longer available or to supplement expertise. Second, only 24 individuals, including the chairs and working group cochairs, met in person during the 2018 World TSC Conference in Dallas, TX, USA, because updates did not need to be as extensive as the changes between 1998 and 2013. Over the next two years, working group cochairs engaged their working group members to review relevant literature and draft an update to their working group’s recommendations. A comprehensive literature search was performed on May 10, 2018, to prepare for discussions on July 25 and 26, 2018. This search used the same terms as the previous update with two exceptions. First, additional literature searches addressing key questions not included by (or more recent than) the general search were performed as needed by each individual working group. To assess the strength of evidence and resulting recommendations, the same National Comprehensive Cancer Network Clinical Guidelines framework was used as before (Table 1). These 2021 International Tuberous Sclerosis Complex Consensus Group surveillance and management recommendations were tasked with drafting new recommendations for each of these areas. In addition, all working groups of the International TSC...
are organized into two sections: (1) recommendations applicable at the time of initial diagnoses and (2) recommendations for ongoing health care. There is some overlap with this approach because certain features discovered upon initial diagnosis may require immediate intervention, additional evaluation, or specialist referral. By necessity, discussion in this article is limited to the most relevant and updated points that differ or have evolved since 2013.

### Diagnostic criteria update

#### Genetic diagnostic criteria

The International TSC Clinical Consensus Group reaffirms the importance of independent genetic diagnostic criteria and clinical diagnostic criteria. Identification of a pathogenic variant in \( TSC1 \) or \( TSC2 \) is sufficient for the diagnosis or prediction of TSC regardless of clinical findings; this is important because manifestations of TSC are known to arise over time at various ages.\textsuperscript{10,11} Genetic diagnosis of TSC prior to an individual meeting clinical criteria for TSC is beneficial to ensure that individuals undergo necessary surveillance to identify manifestations of TSC as early as possible to enable optimal clinical outcomes.

Determination of pathogenicity of genetic variants of \( TSC1 \) or \( TSC2 \) should follow standards and guidelines of the American College of Medical Genetics (ACMG) for interpretation of sequence variants,\textsuperscript{12} now widely adopted as the international standard. Broadly, a "pathogenic" variant is one that clearly prevents protein synthesis and/or inactivates the function of the \( TSC1 \) or \( TSC2 \) proteins (e.g., nonsense or frameshift variants, large genomic deletions) or is a missense variant whose effect on protein function has been established by functional assessment.\textsuperscript{13-16} \( TSC1 \) and \( TSC2 \) variants whose effect on protein synthesis or function is less certain are not definitely pathogenic and would not be considered diagnostic unless supported by additional ACMG criteria for pathogenicity.\textsuperscript{17} Many pathogenic variants identified to date have been carefully curated (www.lovd.nl/TSC1, www.lovd.nl/TSC2), but it should be noted that novel pathogenic variants in \( TSC1 \) or \( TSC2 \) continue to be identified as genetic testing is increasingly accessible and utilized. If the pathogenic variant in an affected relative is known, targeted testing for known familial variants has very high predictive value for family members.

Between 10% and 15% of patients with TSC meeting clinical diagnostic criteria have no mutation identified by conventional genetic testing.\textsuperscript{18} Therefore, failure to identify a pathogenic variant in \( TSC1 \) or \( TSC2 \) does not exclude a diagnosis of TSC.

#### Clinical diagnostic criteria

The clinical diagnostic criteria as established at the 2012 Consensus Conference\textsuperscript{4} were reviewed by each working group, who then recommended whether to keep, change, add, or delete specific major or minor criteria. The new diagnostic clinical criteria have only two changes from the previous version and now include 11 major features and seven minor features (Table 2). The previous major clinical diagnostic criterion of “cortical dysplasias” was found to be too nonspecific in practice and potentially confusing to clinicians, given that TSC is one of several causes of focal cortical dysplasias. The new criterion is “multiple cortical tubers and/or radial migration lines,” which is more specific to TSC.

The dermatology and dental working group recommended adding back the minor clinical diagnostic criteria “sclerotic bone lesions.” Sclerotic bone cysts had been eliminated in 2012 as a minor clinical criterion. However, in the intervening years, working group members observed heightened and unwarranted concern among some medical care providers about the possibility of metastatic cancer. Sclerotic bone lesions are commonly observed in individuals with TSC when high-resolution chest computed tomography (CT) is performed as surveillance for renal angiomyolipoma.\textsuperscript{21,22} These bone lesions are common and relatively specific for TSC.\textsuperscript{22} It is important that clinicians understand that these lesions are not surprising in TSC and rarely require intervention, and they should not raise undue alarm of possible cancer.

### Surveillance and management recommendations for individuals with newly suspected or newly diagnosed TSC

Recommendations are summarized in Table 3. The strength of each of the following recommendations is Category 3 unless specified otherwise.

#### Supporting Evidence:

Class I: evidence provided by a prospective, randomized controlled clinical trial with masked outcome assessment, in a representative population.

Class II: evidence provided by a prospective matched group cohort study in a representative population with masked outcome assessment.

Class III: evidence provided by other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment.

Class IV: evidence provided by uncontrolled studies, case series, case reports, or expert opinion.
TABLE 2.
Diagnostic Criteria

<table>
<thead>
<tr>
<th>Major Criteria</th>
<th>Minor Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypopigmented macules (≥3; at least 5 mm diameter)</td>
<td>“Confetti” skin lesions</td>
</tr>
<tr>
<td>Angiofibroma (≥3) or fibrous cephalic plaque</td>
<td>Dental enamel pits (≥3)</td>
</tr>
<tr>
<td>Ungual fibromas (≥2)</td>
<td>Intraoral fibromas (≥2)</td>
</tr>
<tr>
<td>Shagreen patch</td>
<td>Retinal achromic patch</td>
</tr>
<tr>
<td>Multiple retinal hamartomas</td>
<td>Multiple renal cysts</td>
</tr>
<tr>
<td>Multiple cortical tubers and/or radial migration</td>
<td>Nonrenal hamartomas</td>
</tr>
<tr>
<td>lines</td>
<td></td>
</tr>
<tr>
<td>Subependymal nodule (≥2)</td>
<td>Sclerotic bone lesions</td>
</tr>
<tr>
<td>Subependymal giant cell astrocytoma</td>
<td></td>
</tr>
<tr>
<td>Cardiac rhabdomyoma</td>
<td></td>
</tr>
<tr>
<td>LAM*</td>
<td></td>
</tr>
<tr>
<td>Angiomyolipomas (≥2)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations:
- LAM = Lymphangiomyomatosis
- TSC = Tuberous sclerosis complex

**Definite TSC**: 2 major features or 1 major feature with 2 minor features.

**Possible TSC**: either 1 major feature or ≥2 minor features.

**Genetic diagnosis**: A pathogenic variant in TSC1 or TSC2 is diagnostic for TSC (most TSC-causing variants are sequence variants that clearly prevent TSC1 or TSC2 protein production. Some variants compatible with protein production [e.g., some missense changes] are well established as disease-causing; other variant types should be considered with caution).

* A combination of the 2 major clinical features LAM and angiomyolipomas without other features does not meet criteria for a definite diagnosis.

**Genetics**

All individuals should have a three-generation family history obtained to determine if additional family members are at risk of the condition. Genetic testing is recommended for genetic counseling purposes or when the diagnosis of TSC is suspected or in question but cannot be clinically confirmed (Category 1).

**Brain**

All individuals suspected of having TSC, regardless of age, should undergo MRI of the brain to assess for the presence of cortical or subcortical tubers, other types of neuronal migration defects, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs). If MRI is not available or cannot be performed, CT or head ultrasound (in neonates or infants when fontanels are open) may be used, although these frequently will not detect all abnormalities revealed by MRI21,24 (Category 1).

Recently, gadolinium deposition in the brain has drawn attention,25 although newer macrocyclic gadolinium agents lower the risk of depositions compared with older linear gadolinium agents26,27 and the long-term clinical implications are unknown.25,28 Although gadolinium can be used to better demonstrate SEGAs, in light of the need for repeated scans during childhood and potential side effects of contrast agents, combined

**TABLE 3.**
Surveillance and Management Recommendations for Newly Diagnosed or Suspected TSC

<table>
<thead>
<tr>
<th>Organ System or Specialty Area</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics</td>
<td>Obtain three-generation family history to assess for additional family members at risk of TSC. Offer genetic testing for family counseling or when TSC diagnosis is in question but cannot be clinically confirmed.</td>
</tr>
<tr>
<td>Brain</td>
<td>Obtain MRI of the brain to assess for the presence of tubers, SEN, migrational defects, and SEGA. During infancy, educate parents to recognize infantile spasms and focal seizures, even if none have occurred at the time of first diagnosis. Obtain baseline routine EEG while awake and asleep. If abnormal, especially if features of TAND are also present, follow-up with 8- to 24-h video-EEG to assess for seizure activity.</td>
</tr>
<tr>
<td>TAND</td>
<td>Perform comprehensive assessment for all levels of potential TAND manifestations (see Fig of TAND umbrella for details of levels). Refer as appropriate to suitable professionals to initiate evidence-based interventions based on the TAND profile of above-identified needs. Provide parent/caregiver education and training about TAND to ensure families know what to look out for in emerging TAND manifestations (e.g., autism spectrum disorder, language disorders, attention-deficit/hyperactivity disorder, anxiety disorders). Provide psychological and social support to families around diagnosis, coming to terms with the diagnosis of TSC and TAND, and ensure strategies are in place to support caregiver well-being.</td>
</tr>
<tr>
<td>Kidney</td>
<td>Obtain MRI of the abdomen to assess for the presence of angiomyolipomas and renal cysts. Screen for hypertension by obtaining an accurate blood pressure. Evaluate renal function by determination of GFR.</td>
</tr>
<tr>
<td>Lung</td>
<td>Inquire about tobacco exposure, connective tissue disease manifestations, signs of chyle leak, and pulmonary manifestations of dyspnea, cough, and spontaneous pneumothorax in all adult patients with TSC. Perform baseline chest CT in all females, and symptomatic males, starting at age 18 years or older. Perform baseline PFTs and 6MWT in patients with evidence of cystic lung disease consistent with LAM on the screening chest CT.</td>
</tr>
<tr>
<td>Skin</td>
<td>Perform a detailed clinical dermatologic inspection/examination.</td>
</tr>
<tr>
<td>Teeth</td>
<td>Perform a detailed clinical dental inspection/examination.</td>
</tr>
<tr>
<td>Heart</td>
<td>Consider fetal echocardiography to detect individuals with high risk of heart failure after delivery when rhabdomyomas are identified via prenatal ultrasound. Obtain an echocardiography in pediatric patients, especially if younger than age three years. Obtain an electrocardiography at all ages to assess for underlying conduction defects.</td>
</tr>
<tr>
<td>Eye</td>
<td>Perform a complete ophthalmologic evaluation, including dilated fundoscopy, to assess for retinal findings (astrocytic hamartoma and achromic patch) and visual field deficits.</td>
</tr>
</tbody>
</table>

Abbreviations:
- 6MWT = 6-Minute walk test
- CT = Computed tomography
- EEG = Electroencephalography
- GFR = Glomerular filtration rate
- LAM = Lymphangiomyomatosis
- MRI = Magnetic resonance imaging
- PFT = Pulmonary function test
- SEGA = Subependymal gain cell astrocytoma
- SEN = Subependymal nodules
- TAND = TSC-associated neuropsychiatric disorder
- TSC = Tuberous sclerosis complex
with noncontrast imaging sequences generally sufficient for screening for SEGA, we recommend avoiding contrast agents until there is a growing lesion or clinical suspicion of SEGA. In the latter circumstances, gadolinium can better define the lesion size, characteristics, and margins and nearby anatomical structures, which may be important for decision-making and for planning and monitoring treatment response.

Focal seizures and epileptic spasms occur in most (63% to 78%) infants with TSC, and caregivers should be educated to recognize these even if none are reported at the time of diagnosis. A helpful resource is the Infantile Spasms Action Network (https://infantilespasms.org/what-can-it-look-like/). Also, at the time of diagnosis, children with TSC should undergo routine baseline electroencephalography (EEG), prolonged if necessary to include both awake and sleep stages, even if patient has never reported clinical seizures or epileptic spasms previously. If epileptic spasms or focal seizures are suspected but cannot be confirmed clinically or the baseline EEG reveals abnormalities that are nonspecific, the patient should have an eight- to 24-hour video-EEG that includes neurological outcomes, and pre-emptive treatment with vigabatrin may not be able to improve developmental and neurological outcomes over that achieved by vigabatrin before the onset of clinical seizures may provide additional benefit of preventing or delaying seizure onset in at-risk infants diagnosed with TSC and epileptiform activity on EEG. However, pre-emptive treatment with vigabatrin may not be able to improve developmental and neurological outcomes over that achieved by early recognition and control of clinical seizures alone (Category 2A).

Children with TSC should be referred initially to a pediatric neurologist with expertise in epilepsy associated with TSC. Likewise, adults with TSC should be evaluated by an adult neurologist with expertise in epilepsy associated with TSC. Ongoing management may then be coordinated with a general pediatrician or general neurologist if preferred or necessary (e.g., in regions or countries with limited availability or access to epilepsy or TSC specialists).

**TSC-associated neuropsychiatric disorders (TAND)**

The term, “TAND,” and related terminology was introduced in 2013 and readily accepted as an umbrella term encompassing interrelated neuropsychiatric manifestations common in TSC, including behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties and disorders (Fig.). TAND issues are common and are often the most impactful aspect of TSC, yet they are least likely to be addressed and controlled by existing treatments. The TAND Checklist (lifetime version, TAND-L) was developed in 2015 as a screening tool to identify neuropsychiatric concerns in a person of any age by encouraging and guiding conversations between individuals or caregivers and a health care provider. The TAND Checklist is freely available and can be downloaded in 19 languages (https://tandconsortium.org/checklists/).

At diagnosis, all patients should receive comprehensive assessment for TAND manifestations to identify areas needing immediate or early intervention (Category 1). Patients should be referred as appropriate to suitable professionals to initiate evidence-based interventions for any difficulties or disorders identified (Category 1), and parents or caregivers of children and dependent adults should be educated about TAND to ensure that families know what to look for as potential emerging TAND manifestations (Category 2A). Family members may also need psychological and social support while coming to terms with the diagnosis of TSC and TAND, so strategies should be in place to support caregiver well-being (Category 2B).

**Kidney**

At the time of diagnosis, abdominal imaging should be obtained regardless of age. MRI is the preferred modality for the evaluation of angiomylipoma because 25% to 30% can be fat poor and may be missed when abdominal ultrasonography is performed. In the event MRI is not possible an abdominal CT would be the next preferred modality. Intravenous contrast can help with identification of renal cysts and lipid-poor angiomylipoma on abdominal CT and is likely less harmful than previously feared, especially in patients with normal renal function (glomerular filtration rate [GFR] >60 mL/min/1.73 m²).

MRI of the brain and abdomen can be coordinated, thereby limiting the need for multiple sessions of anesthesia if needed for successful MRI. MRI of the abdomen may also reveal aortic aneurysms or extrarenal hamartomas of the liver and neuroendocrine tumors in the pancreas and other abdominal organs that also can occur in individuals with TSC. In addition to imaging, accurate blood pressure assessment is important because of the increased risk of secondary hypertension. To assess kidney function at time of diagnosis, blood tests should be obtained to determine GFR using creatinine or cystatin C equations for adults or children. Patients with reduced muscle mass for any reason, including significant developmental delays, can have artifactually increased estimated GFR if a creatinine equation is used. In such situations, measurement of serum cystatin C concentration can be used to more accurately evaluate GFR (Category 1).

**Lung**

Clinical assessment for LAM and chest CT should be performed in all females, and symptomatic males, 18 years or older. Ultra-low-dose CT acquisition protocols are recommended when possible to limit radiation exposure. High-resolution CT (HRCT) is not needed to diagnose cysts that are characteristic of LAM but can be useful for the differentiation of dependent abnormalities such as pleural/ chylous effusions or dependent atelectasis. Minimum intensity projection-reformatted images also can be used to better identify extremely small cysts.

Key elements of history include information about family history of lung diseases, occupational and environmental exposures, tobacco use, features of connective tissue diseases, dyspnea on exertion, cough, hemoptysis, chest pain, and history of pneumothorax. Baseline pulmonary function tests (PFTs) including prebronchodilator spirometry and postbronchodilator spirometry, lung volumes, and diffusion capacity of the lung for carbon monoxide, and six-minute walk test should be performed in individuals with lung cysts consistent with LAM on the screening CT. Although in cross-sectional studies serum vascular endothelial growth factor-D (VEGF-D) has excellent positive and moderate negative predictive value for the presence of LAM in women with TSC, it has not been tested prospectively as a screening tool to signal the need for a CT and cannot yet be routinely recommended for that purpose (Category 2A).

Multifocal micronodular pneumocyte hyperplasia (MMPH) refers to benign, nodular proliferation of type II pneumocytes that occurs in both men and women with TSC. Radiologically, MMPH appears as multiple, often diffusely distributed, discrete solid and ground glass nodules, typically ranging between 2 and 14 mm in diameter, with no consistent central/peripheral or apical/basal distribution. Given that MMPH has rarely been reported in...
patients with sporadic LAM, and that non-MMPH nodules are often radiologically indistinguishable from MMPH, the panel recommends that a radiological diagnosis of MMPH should not be a diagnostic criterion for TSC. A lung biopsy of nodules for the purpose of establishing the diagnosis of TSC is not recommended.

**Skin**

Comprehensive dermatologic evaluation by an experienced specialist is recommended at the time of diagnosis for all patients. Wood’s lamp is helpful in detecting hypomelanotic macules. Anticipatory guidance regarding expectations and potential treatments is advised. Sun protection is recommended, for both adults and children, considering the photosensitivity of hypomelanotic macules and the presence of mutations consistent with those induced by ultraviolet radiation in angiofibromas. Intervention with mechanistic target of rapamycin (mTOR) inhibitors (mTORis), pulsed-dye or ablative lasers, or surgical excision can be appropriate for large or disfiguring lesions and for lesions prone to bleeding or a source of pain.

**Teeth**

For newly diagnosed infants, baseline oral evaluation and establishment of a primary dental care provider is recommended at the time of the eruption of the first tooth or no later than age 12 months. If an oral evaluation has not been completed, a baseline evaluation is recommended at the time of diagnosis. A simple technique of utilizing dental disclosing solution can assist the practitioner in delineating the enamel pits more effectively. Solitary lesions (intraoral fibromas or enamel pit) may occur in the general population. If the practitioner identifies multiple lesions, however, it would be prudent to screen for other TSC-related findings (Category 2B).

**Heart**

All individuals should have age-appropriate cardiac evaluation at the time of diagnosis. In pediatric patients, especially younger than age three years, an echocardiography and a 12- to 15-lead electrocardiography (ECG) should be obtained to evaluate for rhabdomyomas and arrhythmias, respectively. In those individuals with rhabdomyomas identified via prenatal ultrasound, fetal echocardiography may be useful to detect those individuals with high risk of heart failure after delivery (Category 1).

In the absence of cardiac symptoms or concerning medical history, echocardiography is not necessary in adults, but as conduction defects may still be present and may influence medication choice and dosing, a baseline ECG is still recommended (Category 2A).

---

**FIGURE.** Spectrum of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorder (TAND) levels and features in TSC. Courtesy of Petrus de Vries, Anna Jansen, and Stephanie VanClooster on behalf of the International TAND Consortium (https://tandconsortium.org/about/). The color version of this figure is available in the online edition.
Eye

A baseline ophthalmologic evaluation, including dilated fundoscopic examination, is recommended for all individuals diagnosed with TSC to screen for retinal astrocytic hamartomas and retinal achromic patches. Retinal astrocytic hamartomas are observed in 30% to 50% of patients with TSC, are bilateral in 43% of cases, and multiple in 40%. These lesions are located most frequently in the posterior pole, along the vascular arcades, and adjacent to the optic nerve.76 (Category 1).

Other

Although vascular aneurysms, gastrointestinal polyps, bone cysts, and various endocrinopathies can be associated with TSC, there is insufficient evidence to support routine evaluation at the time of diagnosis unless there are clinical symptoms or other concerning history that warrants specific investigation.

Ongoing surveillance and management recommendations for individuals previously diagnosed with TSC

Recommendations are summarized in Table 4. The strength of each of the following recommendations is Category 3 unless otherwise specified.

Genetics

Genetic testing and counseling should be offered to individuals with TSC and first-degree relatives where this has not been done previously. All affected individuals should be offered clinical assessment and genetic testing in the form of a TSC1 and TSC2 panel. When a pathogenic variant has been identified in the index case, genetic testing should be offered to at least the first-degree relatives (Category 1).

Subependymal giant cell astrocytoma (SEGA)

Individuals with SEGAs presenting with acute deterioration due to obstructive hydrocephalus, or tumoral hemorrhage, should undergo urgent surgical treatment. Minimally invasive surgical techniques are becoming available and may increase surgical safety in selected patients. Endoscopic resections are applicable to relatively small lesions, but are not widely used.71-73 Laser interstitial thermal therapy has been described in case reports, but long-term results are lacking.74,75 Early treatment is recommended, and experienced surgical teams are a prerequisite for balanced decision-making and reduced patient morbidity and mortality.72,76,77 For large tumors, treatment of hydrocephalus with cerebrospinal fluid diversion such as a temporary external ventricular drain or ventriculoperitoneal shunt may still be required,78 and if the clinical condition allows, neoadjuvant treatment with an mTORI may facilitate surgery by tumor shrinkage, improving tumor-brain interface and reducing tumor vascularity.79 Treatment of large, symptomatic SEGA with an mTORI in lieu of urgent surgery80 or to relieve obstruction is associated with dose. Early treatment is recommended, and experienced surgical teams are a prerequisite for balanced decision-making and reduced patient morbidity and mortality.72,76,77 For large tumors, treatment of hydrocephalus with cerebrospinal fluid diversion such as a temporary external ventricular drain or ventriculoperitoneal shunt may still be required,78 and if the clinical condition allows, neoadjuvant treatment with an mTORI may facilitate surgery by tumor shrinkage, improving tumor-brain interface and reducing tumor vascularity.79 Treatment of large, symptomatic SEGA with an mTORI in lieu of urgent surgery80 or to relieve obstruction is associated with dose. Early treatment is recommended, and experienced surgical teams are a prerequisite for balanced decision-making and reduced patient morbidity and mortality.72,76,77 For large tumors, treatment of hydrocephalus with cerebrospinal fluid diversion such as a temporary external ventricular drain or ventriculoperitoneal shunt may still be required,78 and if the clinical condition allows, neoadjuvant treatment with an mTORI may facilitate surgery by tumor shrinkage, improving tumor-brain interface and reducing tumor vascularity.79 Treatment of large, symptomatic SEGA with an mTORI in lieu of urgent surgery80 or to relieve obstruction is associated with dose.
<table>
<thead>
<tr>
<th>Organ System or Specialty Area</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics/Brain</td>
<td>Offer genetic testing and family counseling if not done previously. Obtain MRI of the brain every 1-3 yr in asymptomatic patients with TSC younger than age 25 yr to monitor for new occurrence of SEGAs. Patients with large or growing SEGAs, or with SEGAs causing ventricular enlargement who are asymptomatic, should undergo MRI scans more frequently, and the patients and their families should be educated regarding the potential of new symptoms. Patients with asymptomatic SEGAs in childhood should continue to be imaged periodically as adults to ensure there is no growth. Surgical resection should be performed for acutely symptomatic SEGAs. Cerebrospinal fluid diversion (shunt) may also be necessary. Either surgical resection or medical treatment with mTORi may be used for growing but otherwise asymptomatic SEGAs. For large tumors, if clinical condition enables, neoadjuvant treatment with mTORi may facilitate surgery. Minimally invasive surgical techniques may increase surgical safety in selected patients. In determining the best treatment option, discussion of the complication risks, adverse effects, cost, length of treatment, and potential impact on TSC-associated comorbidities should be included in the decision-making process. Obtain routine EEG in asymptomatic infants with TSC every 6 weeks up to age 12 months and every 3 months up to age 24 months, as abnormal EEG frequently precedes onset of clinical seizures. Obtain routine EEG in individuals with known or suspected seizure activity. The frequency of routine EEG should be determined by clinical need rather than a specific defined interval. Prolonged video-EEG, 24 hr or longer, is appropriate when seizure occurrence is unclear or when unexplained sleep, behavioral changes, or other alteration in cognitive or neurological function is present. Vigabatrin is the recommended first-line therapy for infantile spasms. ACTH, synthetic ACTH, or prednisolone can be used if treatment with full-dose vigabatrin for 2 weeks has not correlated with clinical and EEG improvement. Other than infantile spasms, antiseizure medications for other seizure types in TSC should generally follow that of other epilepsies. Everolimus and a specific cannabidiol formulation are approved by regulatory authorities for treatment of seizures associated with TSC. No comparative effectiveness data exist to recommend antiseizure medications, everolimus, cannabidiol, or dietary therapies over one another in specific subsets of patients. Epilepsy surgery should be considered for TSC patients with refractory seizures, seizures particularly after failing three medications. Special consideration should be given to children at younger ages experiencing neurological regression, and evaluation for surgery should be performed at centers with experience and expertise in TSC. Perform annual screening for TAND, using validated screening tools such as the TAND Checklist (<a href="https://tandconsortium.org/checklists">https://tandconsortium.org/checklists</a>). Screening may be done more frequently depending on clinical needs. When any concerns are identified on screening, proceed to further evaluations by appropriate professionals to diagnose and treat the relevant TAND manifestations. Perform comprehensive formal evaluation for TAND across all levels of TAND (see Fig of TAND umbrella) at key developmental time points: infancy (0-3 yr), preschool (3-6 yr), premiddle school (6-9 yr), adolescence (12-16 yr), early adulthood (18-25 yr), and as needed thereafter. Refer to appropriate professionals for the management/intervention of relevant TAND manifestations. Interventions should be personalized to the TAND profile of each individual and be based on evidence-based practice guidelines/practice parameters for individual manifestations (e.g., autism spectrum disorder, attention-deficit/hyperactivity disorder, anxiety disorder). Aim for early identification of TAND manifestations and early intervention. Many people with TSC have academic/scholastic difficulties. Therefore, always consider the need for an individual educational program. Sudden and unexpected change in behavior should prompt physical evaluation to look at potential medical causes (e.g., SEGAs, seizures, renal disease, medications). Provide psychological and social support to families and caregivers and ensure strategies are in place to support caregiver well-being. Continue to provide parent/caregiver education and training about TAND to ensure families know what to look out for in emerging TAND manifestations across the lifespan. Obtain MRI of the abdomen to assess for the progression of angiomyolipoma and renal cystic disease every 1-3 years throughout the lifetime of the patient. Assess renal function including determination of glomerular filtration rate, proteinuria, and blood pressure at least annually. Embolization followed by corticosteroids is the first-line therapy for angiomyolipoma presenting with acute hemorrhage. Nephrectomy is to be avoided. For asymptomatic, growing angiomyolipoma measuring larger than 3 cm in diameter, treatment with an mTORi is the recommended first-line therapy. Selective embolization or kidney-sparing resection are acceptable second-line treatments for asymptomatic angiomyolipoma. Inquire about smoking, occupational exposures, connective tissue disease symptoms, chyle leak, and pulmonary manifestations, such as dyspnea, cough, and spontaneous pneumothorax in all adult patients at each clinic visit. For adult females with a negative screening chest CT who remain asymptomatic, repeat to screen for the presence of LAM every 5-7 years through menopause. For patients with evidence of cystic lung disease consistent with LAM on screening chest CT, follow-up scan intervals should be determined on a case-by-case basis depending upon the individual circumstances, such as the presence or absence of symptoms, the ability to perform reliable PFTs, pre-existing use of mTORis for other TSC indications, treatment response (or the lack thereof), or development of other pulmonary complications. Perform routine serial pulmonary function test monitoring at least annually in patients with evidence of LAM on chest CT, and more frequently in patients who are progressing rapidly or who are being monitored for response to therapy. Use mTORi for treatment of LAM in patients with abnormal lung function (FEV1 &lt; 70% predicted), physiological evidence of substantial disease burden (abnormal DLCO &lt;80% or less than lower limit of normal [when available]), air trapping (RV &gt; 120%), resting or exercise-induced oxygen desaturation, rapid decline (rate of decline in FEV1 &gt; 90 mL/year), and problematic chylous effusions. Counsel patients regarding the risk of pregnancy and exogenous estrogen use. Avoid routine use of hormonal therapy or doxycycline for the treatment of LAM. Advise patients against tobacco smoke exposure including the use of electronic cigarettes and vaping. Trial inhaled bronchodilators in patients with symptoms of wheezing, dyspnea, chest tightness, or obstructive defect on spirometry, with continued use in patients who derive symptomatic benefit. Consider measurement of annual VEGF-D levels in patients who are unable to perform reliable pulmonary function tests to monitor adequacy of pharmacodynamic suppression of the mTOR pathway.</td>
</tr>
</tbody>
</table>
Tuberous sclerosis complex

Encourage age-appropriate vaccinations, such as annual influenza vaccination, inactivated recombinant shingles vaccination, and both 13-valent and 23-valent pneumococcal vaccinations. Patients on mTOR inhibitors should receive the recombinant varicella vaccine regardless of age and avoid all live vaccines. Educate patients and families about the signs and symptoms of a pneumothorax and advise them to seek medical attention if they experience any of these symptoms. Offer pleurodesis following the first episode of pneumothorax rather than waiting for a recurrent event. Counsel patients that pleurodesis does not preclude future lung transplantation.

Skin

Perform annual skin examinations for children with TSC. Adult dermatologic evaluation frequency depends on the cutaneous manifestation. Close surveillance and intervention are generally recommended for TSC-related skin lesions that rapidly change in size and/or number; cause functional interference, pain, or bleeding; or inhibit social interactions.

Provide ongoing education on sun protection.

For flat or minimally elevated lesions, topical mTOR treatment is recommended. Watch for improvement in skin lesions over several months; if lesions do not improve, or if earlier intervention is indicated, then consider use of surgical approaches. For protuberant lesions, consider surgical approaches (e.g., excision, lasers).

Teeth

Perform a detailed clinical dental inspection/examination at minimum every 6 months. Take a panoramic radiograph to evaluate dental development or if asymmetry, asymptomatic swelling, or delayed/abnormal tooth eruption occurs. Enamel pits may be managed by preventive measures as first-line treatment (sealants, fluoride). These pits may be managed by restorations if preventive measures fail, or if symptomatic, carious, or there is an aesthetic concern. Symptomatic or deforming oral fibromas and bony jaw lesions should be treated with surgical excision or curettage when present.

Heart

Obtain an echocardiography every 1-3 years in asymptomatic pediatric patients until regression of cardiac rhabdomyomas is documented. More frequent or advanced diagnostic assessment may be required for symptomatic patients. Obtain electrophysiology every 3 to 5 years in asymptomatic patients of all ages to monitor for conduction defects. More frequent or advanced diagnostic assessment such as ambulatory and event monitoring may be required for symptomatic patients.

Eye

Perform annual ophthalmic evaluation for those with or without visual symptoms at baseline. Rare cases of aggressive lesions or those causing vision loss due to their location affecting the fovea or optic nerve may require intervention. mTOR inhibitors have been used with some success to treat problematic retinal astrocytic hamartomas. For patients receiving vigabatrin, there are specific concerns related to visual field loss, which appears to correlate with total cumulative dose. Physicians responsible for monitoring children on vigabatrin can offer serial fundoscopic examinations to detect retinal changes.

Other

Identification of unexpected functional and nonfunctional PNETs have been found during abdominal MRI surveillance in individuals with TSC. Further monitoring and evaluation should be referred to endocrinology.

**TABLE 4.** (continued) Organ System or Specialty Area

<table>
<thead>
<tr>
<th>Organ System or Specialty Area</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Encourage age-appropriate vaccinations, such as annual influenza vaccination, inactivated recombinant shingles vaccination, and both 13-valent and 23-valent pneumococcal vaccinations. Patients on mTOR inhibitors should receive the recombinant varicella vaccine regardless of age and avoid all live vaccines. Educate patients and families about the signs and symptoms of a pneumothorax and advise them to seek medical attention if they experience any of these symptoms. Offer pleurodesis following the first episode of pneumothorax rather than waiting for a recurrent event. Counsel patients that pleurodesis does not preclude future lung transplantation. Seizures in adults with TSC can begin at any age, can worsen, or can abate over the individual's lifespan. Also, seizure semiology can occur with or without TSC (e.g., glioma, subarachnoid hemorrhage, stroke, etc.). Other than for infantile spasms, antiseizure medication or dietary therapy selection in TSC should generally follow that of other epilepsies. The mTOR inhibitor everolimus and a specific formulation of cannabidiol have been specifically evaluated in randomized controlled clinical trials to treat seizures in TSC and found to be effective and well-tolerated (Category 1). Both are now approved by many regulatory authorities for adjunctive treatment of seizures associated with TSC. However, no comparative effectiveness data exist to recommend specific antiseizure medications, everolimus, or cannabidiol over one another in a particular patient. Clinicians should be aware that both everolimus and cannabidiol have important drug interactions with other antiseizure medications, including with each other. Dietary interventions, including a ketogenic diet or low-glycemic index treatment, may be an effective nonpharmacological therapy for patients with TSC with intractable epilepsy, including infantile spasms refractory to vigabatrin and hormonal therapies. Epilepsy surgery should be considered for patients with refractory TSC, particularly after failing three medications. Special consideration should be given to children at younger ages experiencing neurological regression, and evaluation for surgery should be performed at specialized epilepsy centers with experience and expertise in TSC (Category 2A).</td>
<td></td>
</tr>
</tbody>
</table>

(NCT02849457), with results expected in the next year, should address this need. Routine EEG is recommended in individuals with known or suspected seizure activity, but frequency should be determined by clinical need rather than a specifically defined interval. Prolonged (24 hours or longer) video-EEG is appropriate when seizure occurrence is unclear or when unexplained sleep, behavioral changes, or other alteration in cognitive or neurological function is present (Category 2A). Seizures in adults with TSC can begin at any age, can worsen, or can abate over the individual's lifespan. Also, seizure semiology can change in adults with TSC (i.e., focal seizures with impaired awareness may become bilateral, tonic-clonic seizures). Any adult with TSC presenting with new-onset seizures or changed seizure semiology should be examined for non-TSC-related events, which can occur with or without TSC (e.g., glioma, subarachnoid hemorrhage, stroke, etc.). Other than for infantile spasms, antiseizure medication or dietary therapy selection in TSC should generally follow that of other epilepsies. The mTOR inhibitor everolimus and a specific formulation of cannabidiol have been specifically evaluated in randomized controlled clinical trials to treat seizures in TSC and found to be effective and well-tolerated (Category 1). Both are now approved by many regulatory authorities for adjunctive treatment of seizures associated with TSC. However, no comparative effectiveness data exist to recommend specific antiseizure medications, everolimus, or cannabidiol over one another in a particular patient. Clinicians should be aware that both everolimus and cannabidiol have important drug interactions with other antiseizure medications, including with each other. Dietary interventions, including a ketogenic diet or low-glycemic index treatment, may be an effective nonpharmacological therapy for patients with TSC with intractable epilepsy, including infantile spasms refractory to vigabatrin and hormonal therapies. Epilepsy surgery should be considered for patients with refractory TSC, particularly after failing three medications. Special consideration should be given to children at younger ages experiencing neurological regression, and evaluation for surgery should be performed at specialized epilepsy centers with experience and expertise in TSC (Category 2A).
Vagus nerve stimulation can be used in TSC for medically refractory epilepsy if surgery is unsuccessful or not an option. There are early data suggesting that responsive neurostimulation may be effective in select adults with TSC and intractable seizures. TSC-associated neuropsychiatric disorder (TAND) Annual screening for TAND should be performed throughout the lifespan using validated screening tools such as the TAND Checklist (https://tandconsortium.org/checklists/) or more frequently if clinically indicated. If concerns are identified on screening, the individual should be referred for evaluation by appropriate professionals to diagnose and treat the relevant TAND manifestations (Category 1). In addition to annual screening, formal evaluation of TAND is recommended at key developmental time points (Table 4) (Category 2A). This evaluation may require input from a range of professionals including psychiatrists, psychologists, neuropsychologists, or other health care, educational, and neurodevelopmental experts. Sudden and unexpected change in behavior should prompt physical evaluation to look at potential medical causes (e.g., SEGAs, seizures, renal disease, medications). Early identification and intervention for TAND manifestations is important for optimal outcomes. No TSC-specific interventions currently exist for any TAND manifestations. However, evidence-based treatment strategies exist for individual disorders under the TAND umbrella, e.g., autism spectrum disorder, attention-deficit/hyperactivity disorder, and anxiety disorders. Interventions by appropriate specialists should be personalized to the TAND profile of each individual and based on evidence-based practice guidelines or parameters for individual manifestations. Many people with TSC have academic or scholastic difficulties and may benefit from an individualized educational plan (Category 2A). Scholastic difficulties may have an impact on occupational functioning into and throughout adult life. Families and caregivers may also need psychological and social support because of the potential impact of TSC on the entire family, so strategies should be in place to provide or refer to appropriate support (Category 2B). Individuals, families, and caregivers should be educated about TAND so that they can identify emerging TAND manifestations across the lifespan (Category 2B).

Kidney

For asymptomatic, growing angiomylipoma measuring larger than 3 cm in diameter, treatment with an mTORi is recommended as the first-line therapy. The EXIST-2 study demonstrated that in 30% of patients on low-dose everolimus (<5 mg daily), control of angiomylipoma was maintained, and additional evaluations are required every two to seven years for those with new angiomylipoma. At minimum, annual clinical assessment of kidney function, proteinuria, and blood pressure is required in those with normal values, and more frequently in those with findings of renal impairment or hypertension. Transient or variable proteinuria may be a side effect of mTORis but not usually an indication to discontinue treatment. Control of hypertension is also critical, so accurate measurements of blood pressure for patients are crucial, including using age-specific criteria for children. Patients with hypertension should be treated with an inhibitor of the renin-angiotensin-aldosterone system as first-line therapy; current experience does not support previous advice that angiotensin-converting enzyme inhibitors should be avoided in those treated with an mTORi (Category 1). Furthermore, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers clearly prolong kidney function in other chronic kidney disease conditions and have been associated with a reduced rate of angiomylipoma formation when used in the young. The minority of patients who develop advanced renal failure can still benefit from mTORi therapy to prevent bleeding and to possibly slow or stop decline in renal function. For individuals with TSC, all options for renal replacement therapy should be considered, including those with neurological impairment (Category 2B).

Surveillance imaging for polycystic disease, renal cell carcinoma, or other tumors (Category 1) and for changes in angiomylipoma should also be performed. Abdominal MRI, which can be strategically conducted at the same time as brain surveillance imaging, is the preferred imaging modality. However, if MRI is not available, CT scan can be performed. The frequency of imaging should be one to three years, with yearly scans preferred for tumors that are approaching 3 cm in size and/or appear to be growing. Longer intervals are acceptable in some specific situations in which no tumors are seen or only small tumors (<1 cm) are seen with minimal growth over time. Selective embolization followed by corticosteroids, kidney-sparing resection, or ablative therapy for exophytic lesions are acceptable second-line therapy for asymptomatic angiomylipoma if medical treatment with an mTORi is contraindicated. For acute hemorrhage, embolization followed by corticosteroids is more appropriate. Nephrectomy is to be avoided because of the high incidence of complications and increased risk of future renal insufficiency, end-stage renal failure, and the poor prognosis that results from chronic kidney disease (Category 2A).

Fat-poor angiomylipoma are common in patients with TSC, occurring more commonly in children and those with new angiomylipoma. Fat-poor angiomylipoma can be distinguished from carcinoma, because fat-poor angiomylipoma typically have a slower growth velocity (<5 mm/year [in diameter]) than carcinoma. Also, fat-poor angiomylipoma characteristically grow out of the kidney between other structures rather than compressing surrounding structures, which is more commonly a characteristic of carcinoma. When a lesion cannot be confidently identified as a fat-poor angiomylipoma, Vagus nerve stimulation can be used in TSC for medically refractory epilepsy if surgery is unsuccessful or not an option. There are early data suggesting that responsive neurostimulation may be effective in select adults with TSC and intractable seizures.
thereof), or development of other pulmonary complications. When chest CT is performed, the “as low as reasonably achievable” principle should be employed to minimize the radiation dose to the patient (Category 2A).

In individuals with evidence of LAM on CT, baseline PFTs and six-minute walk test should be obtained, and full PFTs should be repeated annually to monitor the rate of disease progression. More frequent spirometry (every three to six months) should be considered in (1) patients with a new LAM diagnosis to establish a trajectory of disease progression, (2) patients with progressive symptoms, (3) patients with advanced disease and limited pulmonary reserves, and (4) to monitor treatment response in patients taking mTORis. Postbronchodilator spirometry is preferred for all patients, to limit variability due to reversible airflow obstruction. In patients who are unable to perform PFTs because of cognitive impairment or other reasons, serial CT imaging may be the best method to assess progression (Category 2A).

The mTORi sirolimus is recommended as the first-line treatment for qualifying patients with LAM (Category 1). In patients unable to perform reliable PFTs, the decision to start sirolimus may be based upon an overall assessment of disease severity and rate of progression as determined by changes in one or more of the following: extent of cystic lung disease on chest CT, need for supplemental oxygen at rest or with exercise, dyspnea on exertion with minimal activities, recurrent pneumothorax, and elevated serum VEGF-D levels. Consideration may also be given to annual measurement of serum VEGF-D levels as a pharmacodynamic marker of treatment effect, although this use of the test has not been validated (Category 2B).

A substantial proportion of patients with TSC who are discovered to have LAM may already be taking everolimus for other indications. In these circumstances, given the extensive molecular similarity and evidence of efficacy in an open-label phase 2 study, we recommend continued treatment with everolimus and serial PFT monitoring rather than switching to sirolimus (Category 2A).

Patients should be counseled that pregnancy in LAM has been associated with accelerated lung function decline and increased risk of pneumothorax. Lung transplantation remains a viable management option for patients with TSC and end-stage LAM. Prior pleurodesis is not a contraindication for lung transplantation. However, the presence of other TSC-related comorbidities, including cognitive impairment, renal dysfunction, or angiomylipoma burden, may influence candidacy as well as outcomes following lung transplantation (Category 2B).

Skin

Annual skin examinations are recommended for children with TSC. The frequency of dermatologic evaluation in adults depends on the severity of cutaneous manifestations. Close surveillance and intervention are recommended for TSC-related skin lesions that rapidly change in size and/or number, cause functional interference, cause pain or bleeding, or inhibit social interactions. Longitudinal follow-up with digital photography may be used to monitor skin changes.

Many individuals show improvement in TSC-related skin lesions while taking a systemic mTORi for other manifestations related to TSC (Category 1). In individuals with an inadequate skin response, surgical approaches may be used, taking into consideration the potential for impaired wound healing while on an mTORi. The risk-benefit ratio of a systemic mTORi generally excludes their use for TSC skin lesions alone. Evidence is currently lacking to demonstrate an additive benefit of topical sirolimus (rapamycin) in patients on systemic therapy.

Topical sirolimus is safe and effective for treating facial angiofibromas (Category 1), and it may also improve other TSC skin lesions (Category 2A). Topical medication is generally applied once or twice daily and compounded by specialty pharmacies at 0.1% to 1% concentration in a variety of vehicles. In Japan, sirolimus gel 0.2% (Rapalimus, Nobelpharma) was approved by regulatory authorities in 2018. Skin lesions that are smaller and flatter appear to respond better to topical sirolimus than bulky lesions, so early treatment is recommended. Long-term therapy will likely be required to maintain benefit. Adverse effects of topical sirolimus are generally mild, such as application-site skin irritation, dry skin, or acne. Systemic absorption of topical sirolimus is typically below the level of detection. Sirolimus has anticancer effects, but one study of topical sirolimus reported increased skin tumors in mice treated with a regimen of topical sirolimus and solar simulated light. Pending clinical studies, good sun protection is recommended while using topical sirolimus.

Surgical approaches can be effective for treating TSC skin lesions (Category 2B). Indications for surgical treatment include bleeding, irritation, pain, disfigurement, or impaired function (including vision, breathing, or mobility). Immediate surgical intervention may be necessary in some patients. For others, the timing of elective surgery should be determined by rate of growth, risk of recurrence, and likelihood of scarring. Younger children with flat angiofibromas may benefit from pulsed-dye laser to reduce facial erythema, whereas use of ablative lasers for larger angiofibromas is preferable in later adolescence when the rate of recurrence is lower. Pulsed-dye laser has minimal risk of dyspigmentation and scarring, but multiple treatments are usually required, and benefits are usually short-lived when used alone. Ablative approaches flatten the lesions, but general anesthesia is often required, and postoperative recovery can take up to a few weeks. Long-term complications include dyspigmentation, scarring, change of skin texture, and regrowth.

Teeth

A detailed clinical dental inspection or examination should be performed at minimum every six months. Patients with special needs and difficulty maintaining oral hygiene may benefit from routine evaluation every three months. A panoramic radiograph may be indicated to evaluate dental development or if asymmetry, asymptomatic swelling, or delayed or abnormal tooth eruption occurs. Enamel pits may be managed by preventive measures as first-line treatment (sealants, fluoride). Enamel pits may be managed by restorations if preventive measures fail, or if symptomatic, carious, or there is an esthetic concern. Symptomatic or deforming oral fibromas and bony jaw lesions should be treated with surgical excision or curettage. Referral to a dentist with advanced training should occur for symptomatic or asymptomatic facial swelling to rule out odontogenic origin or intraoral pain associated with teeth or intraoral lesions.

Heart

Until regression of cardiac rhabdomyomas is documented, follow-up echocardiography should be performed every one to three years in asymptomatic patients. In addition, 12-lead ECG is recommended at minimum every three to five years to monitor for conduction defects. In patients with clinical symptoms, additional risk factors, or significant abnormalities on routine echocardiography or ECG, more frequent interval assessment may be needed and may include ambulatory event monitoring (Category 1). Patients with TSC with known history of arrhythmia or ECG abnormalities that indicate an increased risk for arrhythmia should be
informed that some prescription and nonprescription medications and natural supplements may further increase the risk of arrhythmia. Such individuals should verify the safety and suitability with their cardiologist or TSC specialist before beginning a new medication or supplement.

Eye

For individuals without ophthalmic manifestations of TSC or for those without visual symptoms at baseline, re-evaluation is recommended annually, or as new clinical concerns arise. The majority of retinal astrocytic hamartomas do not cause vision loss; however, rare cases of aggressive lesions or those causing vision loss due to their location affecting the fovea or optic nerve have been reported.168 In such cases intervention with laser, photodynamic therapy, intravitreal anti-VEGF, intravitreal steroids, or surgery may be appropriate.169,170 More recently, mTORis have been used with some success to treat problematic astrocytic hamartomas.171

For patients receiving vigabatrin, there are specific concerns related to visual field loss, which appear to correlate with total cumulative dose.164,165 Serial ophthalmologic examination every three months is recommended by the US Food and Drug Administration. Other modes of surveillance include testing of visual evoked potentials, electroretinography, and optical coherence tomography of the retinal nerve fiber layer. Although these tests can be helpful, they have limitations and are somewhat impractical as they can require sedation. The American Association for Pediatric Ophthalmology and Strabismus supports serial dilated fundus examination for children using vigabatrin166 (Category 2B).

Other

Due to surveillance protocols, there is a growing number of reports of functional and nonfunctional pancreatic neuroendocrine tumors (PNETs) in association with TSC. Functional PNETs are often reported early based on the presence of symptoms. Preliminary reports note instances in which nonfunctional PNETs were missed during early surveillance.167 To address the potential gap in care, the endocrine group recommends special attention to pancreatic lesions on abdominal imaging studies performed for the surveillance of renal lesions and consideration of abdominal MRI with fine pancreatic cuts.168 Compared with other tumor susceptibility syndromes, the risk for endocrine tumors in TSC remains low.169,170 Biopsy of nonfunctional lesions is recommended only when lesions are unusually large, growing, symptomatic, multiple, or exhibit other suspicious characteristics. Functional PNETs require standard-of-care evaluation and management as in patients without TSC.

In the event unexpected thyroid nodules appear on chest CT scans of patients with TSC, those nodules should be evaluated as per standard of care.171 There is no evidence of increased risk of thyroid nodules or thyroid cancer in patients with TSC.172

Other clinical considerations in patients with TSC

The previously published recommendations for surveillance and management of TSC highlighted several key areas regarding care coordination for individuals with TSC. Those guidelines have been translated into 17 languages and primarily focused on the role of specialized TSC clinics and advocacy groups in educating patients, families, and health care professionals on the manifestations, natural history, and care for people with TSC. An important addition to this section concerns the use of mTORis in TSC care, which are approved by many regulatory authorities worldwide and commonly used for certain manifestations of TSC.

Practical guidance for the use of mTOR inhibitors in patients with TSC

The use of mTORis, sirolimus and everolimus, has become the cornerstone in the management of tumors associated with TSC. The first TSC-specific regulatory approval occurred in 2010, when everolimus was approved by the US Food and Drug Administration for the treatment of SEGA. Today, everolimus is now approved in many countries around the world for the treatment of renal angiomyolipoma and/or and partial-onset epilepsy associated with TSC in addition to SEGA. Sirolimus was first approved for the treatment of LAM associated with TSC in Japan in 2014, followed by approval in the United States a year later.

When initiating therapy with an mTORi, baseline laboratory studies should include a fasting lipid panel, comprehensive metabolic panel, cystatin C quantification, urine analysis, and complete blood count with differential. These panels should be repeated shortly after treatment is started in addition to measurements of mTORi trough level and levels of concomitant medications, particularly if they are strong enzyme inhibitors or inducers (e.g., some antiseizure medications such as carbamazepine and oxcarbazepine are known to reduce mTORi trough levels, whereas some antimicrobials such as clarithromycin and ketoconazole are known to increase mTORi trough levels).173 Cannabidiol is reported to increase mTORi trough levels.109,110 Laboratory studies including mTORi trough levels should be rechecked periodically during treatment, particularly when a strong enzyme inhibitor or inducer is introduced to a patient’s treatment regimen. In general, adverse events of systemic therapy with mTORis are mild to moderate,174 including patients treated at young ages.91,93 However, when such therapies are prescribed, it is not uncommon for adverse events, such as oral ulceration, hyperlipidemia, and hyperglycemia, to necessitate dose reduction or temporary suspension of treatment.174,175 Individuals undergoing major surgical procedures while on mTORi therapy should be informed about potential impairment of wound healing and potential immunosuppressive properties that can exacerbate infections in rare instances or impact the safety of immunization with live vaccines (which commonly include vaccines used against measles, mumps, rubella, varicella, and yellow fever).174,175 mTORi therapy also has been associated with menstrual cycle disturbances176 and ovarian cysts.177 Standard practice is to temporary halt mTORi therapy one to two weeks before planned surgeries or live-vaccine immunizations or during any prolonged or new-onset significant infections or other adverse effects and then resume treatment after recovery (typically one to two weeks after vaccination and two to four weeks after surgery). Recurrent or severe adverse events may also require lower dosing of the mTORi when treatment is resumed. Note that benefit has been demonstrated even if resultant blood trough levels of mTORi are at the lower end or even below the recommended reference range (5 to 15 ng/mL).170,178

Quality of life and burden of care

TSC may present a severe physical, mental, and financial burden to both the individuals with TSC and their caregivers. As described previously,41 many individuals with TSC experience TAND. Management of stress associated with TSC and its complexities is crucial to the mental well-being of the individual with TSC and caregivers. Health care providers should help families and caregivers make connections with secondary care teams, including therapists, social workers, and other counselors to learn about their region’s resources such as respite care and other mental health support programs. Caregivers’ and siblings’ physical and mental health should not be overlooked.
Access to care

The International Tuberous Sclerosis Complex Consensus Group is composed of more than 80 TSC specialists from 14 countries (six continents) with a broad range of medical expertise and specialization. These updated consensus recommendations are based on extensive practical experience and best available scientific evidence and as such represent the most up-to-date standard of care for individuals with TSC throughout their lifespan, regardless of where they live. Effort should be made to implement and adhere to these standards fully whenever possible. However, we recognize that significant barriers at the individual, regional, or country level frequently exist that can hinder availability or access to specific technologies, treatments, or medical specialists on which some consensus recommendations depend. The previous guidelines have been translated into 17 languages, and in Portugal these were accepted as care standards for TSC and formally adopted by the National Ministry of Health. Several additional international groups have published their approach to implementing the previous guidelines from 2012; these articles may serve as manuals for regions of similar size, economies, and/or health systems. Local medical providers and specialists may also need to adapt specific recommendations in such circumstances as best as they are able while continuing efforts to remedy and overcome these barriers for the optimal treatment of their patients.

Local and international advocacy groups are essential partners in helping individuals and families navigate the TSC care landscape in their region, providing psychosocial support and educating health care providers and individuals and families affected by TSC. In the United States, the TSC Alliance serves this role (www.tscalliance.org), as do the 38 TSC advocacy groups from different countries of TSC (www.tscinternational.org). TSC has written a companion piece white paper published contemporaneously, Beyond the Guidelines: How we can improve health care for people with tuberous sclerosis complex (TSC) around the world, which focuses the issues of care coordination and access to care through a global lens.

Care coordination and transition of care

Health care transition from pediatric to adult care is challenging in the chronic disease setting, even more so in TSC due to its involvement of many major organ systems requiring focused attention from specialists. Ideally, a multidisciplinary team would manage clinical transition. Two recent papers discuss the transition from pediatric to adult care in greater detail, specifically in the care of individuals with TSC. The Child Neurology Foundation recently convened a multidisciplinary team that produced a consensus statement outlining eight common principles that define the child neurologist’s role in this important transition.

Given the complexities and variety of manifestations across the lifespan, it is essential to have support from a local health care professional available (e.g., primary care physician), in addition to coordinated support from TSC specialists and other care providers that are often located at regional or national referral centers. In countries where government policies to assist patients with rare diseases have not yet been implemented, advocacy group-supported research initiatives centered at teaching hospitals have been instrumental in establishing multispecialty medical teams for the care of individuals with TSC. Secure software for telecommunications may provide additional opportunities for coordinated care among patients, local medical providers, and TSC specialists when medically appropriate and permitted by government regulators.

Acknowledgments

The meeting of International TSC Consensus Group cochairs and working group cochairs at the 2018 World TSC Conference was sponsored and organized by the TSC Alliance. Sponsors of the 2018 World TSC Conference played no role in the planning and did not attend the meeting of the Consensus Group, and they had no influence on the resulting recommendations. Sponsors of the 2018 World TSC Conference were Novartis Pharmaceuticals, the Rothberg Institute for Childhood Diseases, Upsher-Smith Laboratories, LivaNova, Depomed, Greenwich Biosciences, Mallinckrodt Pharmaceuticals, UCB, Lundbeck, Amneal Pharmaceuticals, Aquesthetic Pharmaceuticals, MassMutual, Ovid Therapeutics, West Therapeutics Development and Eolas Pharma, WNC & Associates, and many individual and non-for-profit donors to the TSC Alliance.

References


112. Vabret E, Coughchd C, Lassalle M, Vigneur C. From tuberous sclerosis complex to end stage renal disease: who are these patients? J Nephrol. 2021;34; 677–689.

